What's new? Log in Free sign up

Zura Bio Limited (ZURA) News and press releases

Company Profile

News

From Benzinga Pro

HC Wainwright & Co. Initiates Coverage On Zura Bio with Neutral Rating, Announces Price Target of $5

News, Price Target, Initiation, Analyst Ratings

HC Wainwright & Co. analyst Mitchell Kapoor initiates coverage on Zura Bio (NASDAQ:ZURA) with a Neutral rating and announces Price Target of $5.

Cantor Fitzgerald Reiterates Overweight on Zura Bio

News, Reiteration, Analyst Ratings

Cantor Fitzgerald analyst Josh Schimmer reiterates Zura Bio (NASDAQ:ZURA) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Zura Bio

News, Reiteration, Analyst Ratings

Cantor Fitzgerald analyst Josh Schimmer reiterates Zura Bio (NASDAQ:ZURA) with a Overweight.

Zura Bio Shares Supportive Data From Phase 1 Study Evaluating Lead Candidate, tibulizumab (ZB-106), For Treatment Of Sjogren's Syndrome

These data, along with preclinical data supporting further development of tibulizumab in rheumatoid arthritis (RA), were presented at the Annual European Congress of Rheumatology (EULAR) 2024 in Vienna.

Cantor Fitzgerald Initiates Coverage On Zura Bio with Overweight Rating

News, Initiation, Analyst Ratings

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Zura Bio (NASDAQ:ZURA) with a Overweight rating.

Press releases

From Benzinga Pro

Zura Bio to Present at Three Upcoming Investor Conferences in September

Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseases Expect to initiate Phase 2 studies evaluating

Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has completed

Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the expiration and

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has commenced

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

Tibulizumab (ZB-106) was well tolerated and neutralized IL-17A and BAFF in a Phase 1 study in patients with Sjogren's syndrome Preclinical data demonstrating the potential of dual inhibition of IL-17A and BAFF in a

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.